Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.1,2,4 It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.5 Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.2
Indication Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections.3
Pharmacodynamics Not Available
Mechanism of action Triazavirin is a guanosine nucleotide analog that inhibits RNA synthesis.4,6
Absorption In rabbits, intragastric triazavirin reaches a Cmax of 1.1±0.1mg/L, with a Tmax of 0.40±0.16h, and an AUC of 3.10±0.8mg*h/L.3 In rabbits, intravenous triazavirin has an AUC of 1.2±0.3mg*h/L.3
In humans, triazavirin reaches a Cmax of 4.8µg/mL, with a Tmax of 1-1.5h, and an AUC of 12.8µgµg/h*mL.6
Volume of distribution In rabbits, intragastric triazavirin has a volume of distribution of 83.5±19.2L/kg while intravenous triazavirin has a volume of distribution of 1.2±0.3L/kg.3
Protein binding Data regarding the protein binding of triazavirin is not readily available.
Metabolism Data regarding the metabolism of triazavirin is not readily available.
Route of elimination Data regarding the route of elimination of triazavirin is not readily available.
Half life In rabbits, intragastric triazavirin has a half life of 1.1±0.1h while intravenous triazavirin has a half life of 0.50±0.09h.3
The half life of triazavirin is 1-1.5h.6
Clearance In rabbits, intragastric triazavirin has a clearance of 37.0±11.2L/h*kg while intravenous triazavirin has a clearance of 14.0±3.7L/h*kg.3
The clearance of triazavirin is 246mL/min.6
Toxicity The intraperitoneal LD50 of triazavirin in mice is 1400±120mg/kg in mice and the intragastric LD50 is 2200±96mg/kg.3
Patients experiencing an overdose may present with nausea, vomiting, dyspepsia, and stomach pain.6 Treat overdose with symptomatic and supportive treatment, which may include discontinuation of treatment.6
Pathways Not Available
Pharmacogenomic Effects/ADRs Not Available
In detail https://www.drugbank.ca/drugs/DB15622
|Pcs per package||20 pcs|